These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 30678551)
1. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Saleh K; Khalife-Saleh N; Kourie HR Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551 [No Abstract] [Full Text] [Related]
2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061 [TBL] [Abstract][Full Text] [Related]
4. Atypical autoimmune adverse effects with checkpoint blockade therapies. Friedman CF; Snyder A Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802 [No Abstract] [Full Text] [Related]
5. Cancer immunotherapy in patients with preexisting autoimmune disorders. Donia M; Pedersen M; Svane IM Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287 [TBL] [Abstract][Full Text] [Related]
6. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717 [TBL] [Abstract][Full Text] [Related]
7. Could PD-1/PDL1 immune checkpoints be linked to HLA signature? Correale P; Saladino RE; Nardone V; Giannicola R; Agostino R; Pirtoli L; Caraglia M; Botta C; Tagliaferri P Immunotherapy; 2019 Dec; 11(18):1523-1526. PubMed ID: 31865873 [No Abstract] [Full Text] [Related]
8. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events. Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240 [TBL] [Abstract][Full Text] [Related]
9. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573 [TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy-related adverse events: causes and challenges. Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220 [TBL] [Abstract][Full Text] [Related]
13. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772 [TBL] [Abstract][Full Text] [Related]
15. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Novotny JF; Cogswell J; Inzunza H; Harbison C; Horak C; Averbuch S Ann Oncol; 2016 Oct; 27(10):1966-9. PubMed ID: 27502705 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121 [TBL] [Abstract][Full Text] [Related]
18. Part I: Checkpoint inhibitors in cancer therapy. Daud AI Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535 [No Abstract] [Full Text] [Related]
19. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Nishijima TF; Shachar SS; Nyrop KA; Muss HB Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115 [TBL] [Abstract][Full Text] [Related]